TTNP vs ORMP

For growth investors, Titan Pharmaceuticals, Inc.

(TTNP) is the stronger pick with -100. 0% revenue growth year-over-year, versus -100. 0% for Oramed Pharmaceuticals Inc. (ORMP). Analysts rate Oramed Pharmaceuticals Inc. (ORMP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Oramed Pharmaceuticals Inc.

(ORMP) delivered a total return of -62. 0%, compared to -93. 4% for Titan Pharmaceuticals, Inc. (TTNP). Over 10 years, the gap is even starker: ORMP returned -53. 3% versus TTNP's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Oramed Pharmaceuticals Inc.

(ORMP) is the lower-risk stock at 1. 18β versus Titan Pharmaceuticals, Inc. 's 1. 67β — meaning TTNP is approximately 41% more volatile than ORMP relative to the S&P 500.

By revenue growth (latest reported year), Titan Pharmaceuticals, Inc.

(TTNP) is pulling ahead at -100. 0% versus -100. 0% for Oramed Pharmaceuticals Inc. (ORMP). On earnings-per-share growth, the picture is similar: Titan Pharmaceuticals, Inc. grew EPS 29. 4% year-over-year, compared to -435. 7% for Oramed Pharmaceuticals Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Oramed Pharmaceuticals Inc.

(ORMP) is the more profitable company, earning -1208. 1% net margin versus -280. 5% for Titan Pharmaceuticals, Inc. — meaning it keeps -1208. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ORMP leads at -683. 6% versus -261. 1% for TTNP. At the gross margin level — before operating expenses — TTNP leads at 50. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Oramed Pharmaceuticals Inc.

(ORMP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 18)). Titan Pharmaceuticals, Inc. (TTNP) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ORMP: -53. 3%, TTNP: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.